Eli Lilly and Company (LLY) News
Track canonical SquawkNews coverage tagged to LLY, Eli Lilly and Company. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 183 indexed stories across 51 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Twist Bioscience shares rise after deal with Lilly’s TuneLab
Twist Bioscience said it signed a deal with Eli Lilly’s drug discovery platform Lilly TuneLab, sending TWST up 5% to $144.90 Wednesday. The stock has more than quadrupled over the past year.
EQUITY | Sep 16, 2026, 04:01 PM UTC
L
Haleon reports US sales growth by targeting GLP-1 drug users
Haleon says it is growing US sales of consumer-health products aimed at countering side-effects of weight-loss drugs as GLP-1 use rises.
EQUITY | Sep 16, 2026, 11:26 AM UTC
M
Irish central bank lifts 2026-2027 growth forecasts on AI investment
Ireland’s central bank raised economic growth forecasts for 2026 and 2027 by about half a percentage point, citing stronger consumer spending and a surge in AI-related investment by foreign multinationals.
CENTRAL_BANK | Sep 15, 2026, 11:01 PM UTC
M
Berenberg upgrades Eli Lilly to Buy after obesity-drug demand surge
Berenberg upgraded Eli Lilly to Buy from Hold, citing accelerating obesity-drug demand that could lead to results above the company’s ambitious 2026 outlook. Analyst Kerry Holford also raised her price target.
EQUITY | Sep 15, 2026, 08:31 PM UTC
L
Health-Benefits Platform Thatch Gets $108M in Series C Funding
By Stephen NakrosisThatch, provider of a health-benefits platform, said it raised $108 million in a Series C financing round at a valuation of $1 billion.Thatch said the round saw participation from The General Partnersh
NEWS | Sep 15, 2026, 05:46 PM UTC
L
Thatch Raises $108 Million At $1 Billion Valuation
Thatch
NEWS | Sep 15, 2026, 05:02 PM UTC
L
From Ozempic Face to K-Beauty Factories: The Next Beauty Bet
FROM OZEMPIC FACE TO K-BEAUTY FACTORIES: THE NEXT BEAUTY BETFrom gaunt "Ozempic face" to K-beauty factories quietly powering global skincare, analysts at BCA Research say a multibillion-dollar "beauty economy" is emergin
NEWS | Sep 15, 2026, 03:34 PM UTC
L
Berenberg Lifts Lilly to Buy With a $1,400 Target
Eli Lilly and Co. NYSE:LLY rose 1.27% premarket after Berenberg upgraded it to Buy from Hold and lifted its price target to $1,400 from $1,220, implying roughly 22% upside from current levels. The firm's 2026 return on r
NEWS | Sep 15, 2026, 03:21 PM UTC
L
Novo CEO urges staff to embrace more customer-focused culture
By Jacob Gronholt-PedersenNovo Nordisk's OMXCOP:NOVO_B CEO Mike Doustdar on Tuesday urged employees to be more customer-focused, as the Wegovy maker seeks to regain ground in the fast-growing obesity drug market.The push
NEWS | Sep 15, 2026, 02:30 PM UTC
L
Eli Lilly To Present Fresh Data On Foundayo, Retatrutide In Europe — Here’s Why Berenberg Sees A 21% Potential Upside In LLY Stock
Eli Lilly (LLY) was in the spotlight on Tuesday after Berenberg upgraded the pharmaceutical giant, citing potential upside to its 2026 outlook, as the company prepares to unveil new data later this month for several next
EQUITY | Sep 15, 2026, 01:52 PM UTC
H
Eli Lilly boosted to Buy at Berenberg as upside to 2026 guidance seen
Berenberg upgraded Eli Lilly NYSE:LLY to Buy from Hold, saying that it sees the drugmaker exceeding its 2026 guidance driven by continuing its lead in the weight-loss drugs market.The firm upped its price target to $1400
NEWS | Sep 15, 2026, 01:41 PM UTC
H
Eli Lilly Stock Gains as Retatrutide and Foundayo Data Highlight Pipeline Strength
Shares of Eli Lilly and Company (NYSE: LLY ) are trading higher Tuesday morning following positive previews of its late-stage obesity and diabetes pipeline. Eli Lilly stock is trading near recent highs. What’s next for L
LIVE | Sep 15, 2026, 01:29 PM UTC
L
Lilly to invest in QurCan as part of genetic medicines deal
Canadian biotech QurCan Therapeutics on Tuesday announced an investment from Eli Lilly NYSE:LLY as part of an exclusive research and collaboration agreement with the Indiana-based pharma giant to develop genetic medicine
NEWS | Sep 15, 2026, 11:41 AM UTC
L
LLY - Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
LLY - Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
NEWS | Sep 15, 2026, 10:46 AM UTC
L
Eli Lilly Target Raised to $1,400 From $1,220 by Berenberg
Eli Lilly Target Raised to $1,400 From $1,220 by Berenberg
NEWS | Sep 15, 2026, 05:27 AM UTC
L
Eli Lilly Raised to Buy From Hold by Berenberg
Eli Lilly Raised to Buy From Hold by Berenberg
NEWS | Sep 15, 2026, 05:26 AM UTC
L
Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs
By Mariam SunnyEli Lilly NYSE:LLY on Monday said it has captured more than 30% of new patients in the U.S. market for oral obesity treatments, narrowing the early lead gained by Danish rival Novo Nordisk OMXCOP:NOVO_B wi
NEWS | Sep 14, 2026, 08:32 PM UTC
L
LLY: Obesity treatment portfolio expands with new therapies, digital access, and strong cost-effectiveness data
A broad obesity portfolio is being developed to address diverse patient needs, with foundational and new therapies expanding access and improving outcomes. Cost-effectiveness data and digital initiatives are driving empl
NEWS | Sep 14, 2026, 07:27 PM UTC
L
LLY: Obesity portfolio expansion, access initiatives, and new launches drive growth and innovation
The discussion highlighted a broad obesity portfolio strategy, ongoing efforts to expand access and coverage, and strong early uptake of new therapies like Zepbound and Foundayo. Pipeline assets such as retatrutide and e
NEWS | Sep 14, 2026, 06:56 PM UTC
H
Bulls and Bears: GameStop, Marvell, Robinhood
examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. U.S. stocks ended the week lower despite a Friday rebound, as surging oil prices, rising Treasury
LIVE | Sep 12, 2026, 12:50 PM UTC
L
JPMorgan Tweaks Hims & Hers Stock Outlook on Key Risk
Hims & Hers Health NYSE:HIMS faces a more complicated growth path as regulatory pressure reshapes its weight-loss business, prompting JPMorgan to resume coverage at Neutral with a $32 price target. The target implies rou
EQUITY | Sep 11, 2026, 09:14 PM UTC
L
News On AtaiBeckley Inc. (ATAI) Now Under LLY
News On AtaiBeckley Inc. (ATAI) Now Under LLY
NEWS | Sep 11, 2026, 09:08 PM UTC
H
Eli Lilly completes acquisition of AtaiBeckley
MNA | Sep 11, 2026, 01:02 PM UTC
L
HSBC raises Eli Lilly price target to $940 from $850
Benzinga reports HSBC raised its Eli Lilly price target to $940.00 per share from $850.00.
EQUITY | Sep 10, 2026, 02:07 PM UTC
L
Eli Lilly’s GLP-1 windfall to fund push into women’s health - Bloomberg News
Source link: Note: Reuters has not verified this story and does not vouch for its accuracy
EQUITY | Sep 10, 2026, 01:54 PM UTC
M
Roivant drug meets mid-stage goals; ROIV shares jump premarket
Roivant (ROIV) said its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up about 20% in premarket trading.
EQUITY | Sep 08, 2026, 10:59 AM UTC
M
US study finds GLP-1 weight-loss prescriptions for under-12s up 300-fold
A study published Friday says U.S. prescriptions for GLP-1 weight-loss drugs among children under 12 have risen more than 300-fold since 2019, as doctors seek effective treatments for younger patients with obesity.
EQUITY | Sep 04, 2026, 06:45 PM UTC
H
Aspen Pharmacare targets Mounjaro regional sales over $124M by June 2027
Distributor Aspen Pharmacare expects Mounjaro sales in the region to break 2 billion rand (about $124 million) in the year ending June 2027, supporting Lilly’s African rollout.
EARNINGS | Sep 03, 2026, 09:36 PM UTC
L
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense — Barrons.com
By Paul R. La MonicaWant a prescription for investing success? Check out Big Pharma companies, biotechs, and other healthcare stocks.The healthcare sector has been on a hot streak, trouncing the broader market, and there
EQUITY | Sep 03, 2026, 05:40 PM UTC
H
Aspen expects Mounjaro Africa sales above $124 million in current year
Aspen Pharmacare expects African sales of Eli Lilly’s Mounjaro to exceed 2 billion rand (about $124 million) in its current financial year, citing strong South Africa demand and planned launches in Nigeria and Kenya.
EARNINGS | Sep 03, 2026, 12:36 PM UTC
H
Aspen Pharmacare annual normalised earnings rise 22% on Mounjaro demand
Aspen Pharmacare (APN) reported annual normalised earnings up 22%, citing strong demand for obesity and diabetes treatment Mounjaro it distributes and improving profitability in its manufacturing business.
EARNINGS | Sep 02, 2026, 12:29 PM UTC
M
FDA warns of severe risks from misbranded GLP-1 weight-loss drugs
The FDA warned patients and providers about severe health risks from unapproved and compounded GLP-1 weight-loss drugs, including illegally marketed semaglutide and tirzepatide. Hims & Hers stock closed 3.85% lower Tuesd
REGULATION | Sep 02, 2026, 11:40 AM UTC
L
Lilly to participate in Morgan Stanley 24th Global Healthcare Conference
Lilly will participate in the Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Sep 01, 2026, 02:01 PM UTC
M
Novo Nordisk launches Wegovy pill in Germany
Novo Nordisk (NOVOB) has launched its Wegovy oral weight-loss pill in Germany, a spokesperson said, as investors focus on the treatment amid intensifying competition with Eli Lilly (LLY).
EQUITY | Sep 01, 2026, 08:54 AM UTC
M
LLY to buy Merida in $25B deal
LLY plans to buy Merida in a $25B deal, per TradingView News. TOGETHER data cited.
EQUITY | Sep 01, 2026, 07:14 AM UTC
L
Lilly immunology deal starts Phase 1
Lilly’s $2.88 billion immunology deal has started Phase 1.
EQUITY | Sep 01, 2026, 02:56 AM UTC
L
GLP-1 weight loss drugs effective even at low starter doses
GLP-1 weight loss drugs effective even at low starter doses
EQUITY | Aug 31, 2026, 10:23 PM UTC
L
Health Care Down, But not by Much, Amid Deal Activity
Health Care Down, But not by Much, Amid Deal Activity
EQUITY | Aug 31, 2026, 09:18 PM UTC
L
Ataibeckley-HSR waiting period for Eli Lilly merger expired Aug. 28
The Hart-Scott-Rodino waiting period for the Eli Lilly merger expired on August 28.
MNA | Aug 31, 2026, 08:44 PM UTC
H
Top News Today: Stocks Fall, Oil Rises After U.S.-Iran Clashes Near Strait
Top News Today: Stocks Fall, Oil Rises After U.S.-Iran Clashes Near Strait
ENERGY | Aug 31, 2026, 08:34 PM UTC
L
600,000 seniors have signed up for obesity drugs under new Medicare program
600,000 seniors have signed up for obesity drugs under new Medicare program
EQUITY | Aug 31, 2026, 07:38 PM UTC
L
Hims & Hers offers GLP-1 weight-loss drugs, men's health treatments in Australia
Hims & Hers offers GLP-1 weight-loss drugs, men's health treatments in Australia
EQUITY | Aug 31, 2026, 06:55 PM UTC
L
Eli Lilly CEO: $25B deal spree targets post-obesity growth into 2030s
Eli Lilly CEO says the company’s $25B deal spree is about building growth beyond obesity into the 2030s.
EQUITY | Aug 31, 2026, 05:56 PM UTC
M
Eli Lilly shares fall on $2.9 billion acquisition
Eli Lilly shares fell after the company unveiled a $2.9 billion acquisition.
MNA | Aug 31, 2026, 04:36 PM UTC
L
Trump administration to announce drug pricing deals
TradingView News reports the Trump administration will announce drug pricing deals.
EQUITY | Aug 31, 2026, 04:07 PM UTC
L
Eli Lilly's Next $2.9 Billion Bet Is Not About Obesity
Eli Lilly's Next $2.9 Billion Bet Is Not About Obesity
EQUITY | Aug 31, 2026, 03:36 PM UTC
L
Novo's Wegovy Pill Enters China Behind Lilly
Novo's Wegovy Pill Enters China Behind Lilly
GEOPOLITICS | Aug 28, 2026, 05:56 PM UTC
M
FDA clears Mounjaro for heart risk, boosting LLY catalyst
Eli Lilly says the FDA cleared Mounjaro for heart risk, providing a fresh catalyst for LLY shares.
REGULATION | Aug 28, 2026, 05:26 PM UTC
L
Lilly Mounjaro franchise wins heart-risk label
Lilly’s $9.94 billion Mounjaro franchise wins a heart-risk label.
EQUITY | Aug 28, 2026, 05:06 PM UTC
L
What other health conditions could GLP-1 weight-loss drugs treat?
What other health conditions could GLP-1 weight-loss drugs treat?
EQUITY | Aug 28, 2026, 03:13 PM UTC
M
Eli Lilly FDA win supports weight-loss drug
Eli Lilly says it has scored a major FDA win for its weight-loss drug.
REGULATION | Aug 28, 2026, 02:16 PM UTC
L
Mounjaro Just Opened a Much Bigger Door
Mounjaro Just Opened a Much Bigger Door
EQUITY | Aug 28, 2026, 02:16 PM UTC
L
Mounjaro Vs Trulicity: Eli Lilly’s New FDA Win Puts Its Blockbuster Weight-Loss Drug In Focus
Mounjaro Vs Trulicity: Eli Lilly’s New FDA Win Puts Its Blockbuster Weight-Loss Drug In Focus
REGULATION | Aug 28, 2026, 12:25 PM UTC
H
FDA approval for Mounjaro cardiovascular risk reduction in type 2 diabetes
Eli Lilly’s Mounjaro has received FDA approval to cut cardiovascular risk in type 2 diabetes.
REGULATION | Aug 28, 2026, 11:24 AM UTC
M
US FDA approves Lilly’s Mounjaro to reduce cardiovascular risk
The US FDA approved Lilly’s Mounjaro to reduce cardiovascular risk.
REGULATION | Aug 28, 2026, 11:05 AM UTC
L
Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
EQUITY | Aug 28, 2026, 10:00 AM UTC
L
Novo sends oral Wegovy into China’s GLP-1 race
Novo has sent oral Wegovy into China’s GLP-1 market race behind Lilly.
GEOPOLITICS | Aug 27, 2026, 07:36 PM UTC
L
Eli Lilly sees bigger weight-loss drug opportunity
TradingView News reports Eli Lilly sees a larger weight-loss drug opportunity.
EQUITY | Aug 27, 2026, 12:16 PM UTC
L
Huawei plans for more AI pharma tie-ups, says healthcare president
Huawei plans for more AI pharma tie-ups, says healthcare president
GEOPOLITICS | Aug 27, 2026, 08:25 AM UTC
M
White House to announce Trump drug pricing deals
White House plans to announce Trump’s new drug pricing deals with biotechs companies.
GEOPOLITICS | Aug 27, 2026, 01:26 AM UTC